Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 69 of 727 for:    Area Under Curve AND Bioavailability

A Study to Assess the Absolute Bioavailability of Oral Selumetinib in Healthy Male Volunteers.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02238782
Recruitment Status : Completed
First Posted : September 12, 2014
Results First Posted : April 5, 2016
Last Update Posted : April 5, 2016
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
To assess the absolute bioavailability of oral selumetinib in healthy male volunteers

Condition or disease Intervention/treatment Phase
Healthy Volunteers Bioavailability Study Drug: selumetinib 75mg single dose Other: [14C] selumetinib IV solution Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 21 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Study to Assess the Absolute Bioavailability of a Single Oral Dose of Selumetinib With Respect to an Intravenous Microdose of [14C] Selumetinib in Healthy Male Volunteers
Study Start Date : October 2014
Actual Primary Completion Date : November 2014
Actual Study Completion Date : November 2014

Arm Intervention/treatment
Experimental: selumetinib 75mg single dose
3 capsules of 25 mg administered orally
Drug: selumetinib 75mg single dose
3 capsules of 25 mg given as a single dose
Other Name: Selumetinib

Other: [14C] selumetinib IV solution
single, radiolabeled, IV (infused), microdose (80 μg) of [14C] selumetinib, infused using a syringe pump as a 15-minute infusion, administered 1h 15 min after receiving the oral dose




Primary Outcome Measures :
  1. Absolute Bioavailability [ Time Frame: 0 to 72 hours post-dose ]
    To calculate absolute bioavailability we used the formula: Area Under the Curve (oral dose)/Area Under the Curve (intravenous dose)*100



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Provision of written informed consent
  2. Healthy male volunteers aged 18 to 65
  3. Male volunteers with sexual partners who are pregnant or who could become pregnant should use two highly effective methods of contraception (including one barrier method) for at least 14 days after completing the study and should avoid sperm donation for 14 days after study completion.
  4. Body mass index between 18 and 30 kg/m2 and weighing between 50 and 100 kg.
  5. Use no nicotine containing products for at least 3 months prior to screening with a negative cotinine screen at screening and Day 1 (Visit 2)
  6. Calculated creatinine clearance greater than 50 mL/min using Cockcroft Gault formula.

Exclusion Criteria:

  1. Involvement in the planning and/or conduct of the study
  2. Previous enrolment for treatment in the present study
  3. Japanese or non Japanese Asian or Indian ethnicity.
  4. Any one parent or grandparent is Japanese or non-Japanese Asian or Indian.
  5. Treatment with another new chemical entity or participation in any other clinical study that included drug treatment within at least 3 months
  6. Participation in another clinical study involving administration of [14C] radioactivity within 1 year.
  7. Current or past history of central serious retinopathy or retinal vein thrombosis, intraocular pressure greater than 21 mmHg or uncontrolled glaucoma.
  8. Any clinically significant disease or disorder which, may put the volunteer at risk because of participation in the study, influence the study result or influence the volunteer's ability to participate in the study.
  9. Any clinically relevant abnormal findings in physical examination, haematology, clinical chemistry, urinalysis, vital signs or 12 lead ECG at Visit 1, which may put the volunteer at risk because of his participation in the study.
  10. Use of drugs with enzyme inducing properties such as St John's Wort within 4 weeks prior to the administration of the investigational product
  11. Use of any other prescribed medicine and over the counter drugs within 2 week or 5 times the half life, whichever is longer prior to the administration of the investigational product up to and including the follow up visit (Visit 4), with the exception of occasional use of paracetamol or ibuprofen and over the counter adrenergic nasal spray. No medications known to prolong the QT/corrected QT interval are allowed.
  12. Excessive intake of caffeine containing drinks or food
  13. Any intake of grapefruit and Seville oranges including products containing grapefruit or Seville oranges within 7 days of the admission on Day -1.
  14. History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, or history of hypersensitivity to drugs with a similar chemical structure or class to Selumetinib.
  15. Plasma donation within 1 month of screening (Visit 1) or any blood donation or blood loss greater than 500 mL during the 3 months prior to screening (Visit 1).
  16. History of or current alcohol or drug abuse.
  17. A suspected or manifested infection according to the International Air Transport Association Categories A and B infectious substances.
  18. Positive results on screening tests for HIV and/or hepatitis B and/or hepatitis C.
  19. Baseline LVEF <55% measured by echocardiography.
  20. Planned inpatient surgery, dental procedure or hospitalisation during the study.
  21. Healthy male volunteers who in the opinion of the Principal Investigator, should not participate in the study.
  22. Judgment by Principal Investigator that the volunteer should not participate in the study if they have ongoing or recent minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02238782


Locations
Layout table for location information
United Kingdom
Research Site
Nottingham, United Kingdom
Sponsors and Collaborators
AstraZeneca
Investigators
Layout table for investigator information
Principal Investigator: Stuart Mair Quotient Clinical Ltd

Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT02238782     History of Changes
Other Study ID Numbers: D1532C00080
First Posted: September 12, 2014    Key Record Dates
Results First Posted: April 5, 2016
Last Update Posted: April 5, 2016
Last Verified: March 2016
Keywords provided by AstraZeneca:
bioavailability
pharmacokinetics
I phase
AZD6244
cancer